{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T23:44:50Z","timestamp":1790379890316,"version":"4.1.0"},"reference-count":53,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2024,7,26]],"date-time":"2024-07-26T00:00:00Z","timestamp":1721952000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceuticals"],"abstract":"<jats:p>Psoriasis (PsO) is a chronic inflammatory dermatosis that often presents with erythematous, sharply demarcated lesions. Although psoriasis is primarily a dermatological disease, its immune-mediated pathogenesis produces systemic effects and is closely associated with various comorbid conditions such as cardiovascular disease (CVD), metabolic syndrome (MetS), and diabetes mellitus type II (DMII). Apremilast, an oral phosphodiesterase 4 (PDE-4) inhibitor, has shown promise in treating moderate-to-severe psoriasis and is associated with potential cardiometabolic benefits. In a 12-month prospective observational study involving 137 patients with moderate-to-severe psoriasis, we assessed changes in psoriasis clinimetric scores and metabolic profiles from baseline (T0) to 52 weeks (T1) to evaluate the efficacy of apremilast. After 52 weeks of apremilast treatment, we documented a statistically significant decrease in low-density lipoprotein (LDL) and total cholesterol, triglycerides, and glucose levels. Our findings even suggest a potential synergistic effect among patients treated with apremilast, alongside concomitant statin and\/or insulin therapy. Although the results of our study must be validated on a larger scale, the use of apremilast in the treatment of psoriatic patients with cardio-metabolic comorbidities yields promising results.<\/jats:p>","DOI":"10.3390\/ph17080989","type":"journal-article","created":{"date-parts":[[2024,7,26]],"date-time":"2024-07-26T06:17:44Z","timestamp":1721974664000},"page":"989","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Apremilast as a Potential Targeted Therapy for Metabolic Syndrome in Patients with Psoriasis: An Observational Analysis"],"prefix":"10.3390","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7447-6798","authenticated-orcid":false,"given":"Elena","family":"Campione","sequence":"first","affiliation":[{"name":"Dermatology Unit, Department of Systems Medicine, Tor Vergata University Hospital, 00133 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikkia","family":"Zarabian","sequence":"additional","affiliation":[{"name":"School of Medicine and Health Sciences, George Washington University, 2300 I St NW, Washington, DC 20052, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4025-7882","authenticated-orcid":false,"given":"Terenzio","family":"Cosio","sequence":"additional","affiliation":[{"name":"Department of Experimental Medicine, University of Rome Tor Vergata, Via Montpellier 1, 00133 Rome, Italy"},{"name":"Dynamyc Research Team 7380, Universit\u00e9 de Paris-Est-Cr\u00e9teil, 94000 Cr\u00e9teil, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristiana","family":"Borselli","sequence":"additional","affiliation":[{"name":"Dermatology Unit, Department of Systems Medicine, Tor Vergata University Hospital, 00133 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio","family":"Artosi","sequence":"additional","affiliation":[{"name":"Dermatology Unit, Department of Systems Medicine, Tor Vergata University Hospital, 00133 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riccardo","family":"Cont","sequence":"additional","affiliation":[{"name":"Dermatology Unit, Department of Systems Medicine, Tor Vergata University Hospital, 00133 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Sorge","sequence":"additional","affiliation":[{"name":"Laboratory of Biometry, Department of Systems Medicine, University of Rome Tor Vergata, 00133 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruslana Gaeta","family":"Shumak","sequence":"additional","affiliation":[{"name":"Dermatology Unit, Department of Systems Medicine, Tor Vergata University Hospital, 00133 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1115-4270","authenticated-orcid":false,"given":"Gaetana","family":"Costanza","sequence":"additional","affiliation":[{"name":"Unit of Virology, Department of Experimental Medicine, University of Rome Tor Vergata, Via Montpellier 1, 00133, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonia","family":"Rivieccio","sequence":"additional","affiliation":[{"name":"Dermatology Unit, Department of Systems Medicine, Tor Vergata University Hospital, 00133 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1970-2670","authenticated-orcid":false,"given":"Roberta","family":"Gaziano","sequence":"additional","affiliation":[{"name":"Department of Experimental Medicine, University of Rome Tor Vergata, Via Montpellier 1, 00133 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8697-6896","authenticated-orcid":false,"given":"Luca","family":"Bianchi","sequence":"additional","affiliation":[{"name":"Dermatology Unit, Department of Systems Medicine, Tor Vergata University Hospital, 00133 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,7,26]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1016\/S0140-6736(20)32549-6","article-title":"Psoriasis","volume":"397","author":"Griffiths","year":"2021","journal-title":"Lancet"},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Campanati, A., Marani, A., Martina, E., Diotallevi, F., Radi, G., and Offidani, A. (2021). Psoriasis as an Immune-Mediated and Inflammatory Systemic Disease: From Pathophysiology to Novel Therapeutic Approaches. Biomedicines, 9.","DOI":"10.3390\/biomedicines9111511"},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Barrea, L., Nappi, F., Di Somma, C., Savanelli, M.C., Falco, A., Balato, A., Balato, N., and Savastano, S. (2016). Environmental Risk Factors in Psoriasis: The Point of View of the Nutritionist. Int. J. Environ. Res. Public Health, 13.","DOI":"10.3390\/ijerph13070743"},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Kimmel, G.W., and Lebwohl, M. (2018). Psoriasis: Overview and Diagnosis. Evidence-Based Psoriasis: Diagnosis and Treatment, Springer.","DOI":"10.1007\/978-3-319-90107-7_1"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1590\/abd1806-4841.20153038","article-title":"Psoriasis: Classical and emerging comorbidities","volume":"90","author":"Duarte","year":"2015","journal-title":"An. Bras. De Dermatol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1038\/s41584-019-0256-0","article-title":"Cardiometabolic Comorbidities in ra and PSA: Lessons Learned and future directions","volume":"15","author":"Ferguson","year":"2019","journal-title":"Nat. Rev. Rheumatol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1001\/jama.2020.4006","article-title":"Pathophysiology, Clinical Presentation, and Treatment of Psoriasis: A Review","volume":"323","author":"Armstrong","year":"2020","journal-title":"JAMA"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1007\/s12325-023-02468-3","article-title":"Apremilast use in severe psoriasis: Real-world data from Central and Eastern Europe\u2014Advances in therapy","volume":"40","author":"Cetkovska","year":"2023","journal-title":"Adv. Ther."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1016\/j.bcp.2012.01.001","article-title":"Apremilast mechanism of action and application to psoriasis and psoriatic arthritis","volume":"83","author":"Schafer","year":"2012","journal-title":"Biochem. Pharmacol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"AB192","DOI":"10.1016\/j.jaad.2021.06.780","article-title":"28463 Aprelimast and psoriasis: Significant hemoglobin A1c reduction and improved insulin resistance independent of changes in body mass index","volume":"85","author":"Tadros","year":"2021","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_11","first-page":"113","article-title":"Comorbid Psoriasis and Metabolic Syndrome: Clinical Implications and Optimal Management","volume":"12","author":"Hillary","year":"2022","journal-title":"Psoriasis"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1093\/rheumatology\/keab474","article-title":"Effect of the phosphodiesterase 4 inhibitor apremilast on cardiometabolic outcomes in psoriatic disease\u2014Results of the immune metabolic associations in psoriatic arthritis study","volume":"61","author":"Ferguson","year":"2021","journal-title":"Rheumatology"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1111\/j.1476-5381.2009.00194.x","article-title":"The role of the PDE4D camp phosphodiesterase in the regulation of glucagon-like peptide-1 release","volume":"157","author":"Ong","year":"2009","journal-title":"Br. J. Pharmacol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"2685","DOI":"10.2147\/DMSO.S229549","article-title":"Small Molecules, Big Promises: Improvement of Psoriasis Severity and Glucidic Markers with Apremilast: A Case Report","volume":"12","author":"Lanna","year":"2019","journal-title":"Diabetes Metab. Syndr. Obes. Targets Ther."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"110615","DOI":"10.1016\/j.nut.2019.110615","article-title":"Obesity: A preventable, treatable, but relapsing disease","volume":"71","author":"Romano","year":"2020","journal-title":"Nutrition"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.3899\/jrheum.151376","article-title":"A Phase III, Randomized, Controlled Trial of Apremilast in Patients with Psoriatic Arthritis: Results of the PALACE 2 Trial","volume":"43","author":"Cutolo","year":"2016","journal-title":"J. Rheumatol."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Lemieux, I., and Despr\u00e9s, J.P. (2020). Metabolic Syndrome: Past, Present and Future. Nutrients, 12.","DOI":"10.3390\/nu12113501"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1016\/j.metabol.2014.08.010","article-title":"Diabetic dyslipidemia","volume":"63","author":"Wu","year":"2014","journal-title":"Metab. Clin. Exp."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1093\/eurjpc\/zwaa093","article-title":"Efficacy and safety for the achievement of guideline-recommended lower low-density lipoprotein cholesterol levels: A systematic review and meta-analysis","volume":"28","author":"Khan","year":"2022","journal-title":"Eur. J. Prev. Cardiol."},{"key":"ref_20","first-page":"825","article-title":"The Diagnosis and Treatment of Hypertriglyceridemia","volume":"116","author":"Parhofer","year":"2019","journal-title":"Dtsch. \u00c4rzteblatt Int."},{"key":"ref_21","first-page":"317","article-title":"Erythrocyte Sedimentation Rate and C-reactive Protein Measurements and Their Relevance in Clinical Medicine","volume":"115","author":"Bray","year":"2016","journal-title":"WMJ Off. Publ. State Med. Soc. Wis."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"274","DOI":"10.4103\/ijd.ijd_418_23","article-title":"Psoriasis and its Association with Metabolic Syndrome","volume":"68","author":"Agarwal","year":"2023","journal-title":"Indian J. Dermatol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"adv00545","DOI":"10.2340\/00015555-3846","article-title":"Effectiveness of apremilast in real life in patients with psoriasis: A longitudinal study","volume":"101","author":"Malara","year":"2021","journal-title":"Acta Derm. Venereol."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Meehan, E.V., and Wang, K. (2022). Interleukin-17 Family Cytokines in Metabolic Disorders and Cancer. Genes, 13.","DOI":"10.3390\/genes13091643"},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Hao, Y., Zhu, Y.J., Zou, S., Zhou, P., Hu, Y.W., Zhao, Q.X., Gu, L.N., Zhang, H.Z., Wang, Z., and Li, J. (2021). Metabolic Syndrome and Psoriasis: Mechanisms and Future Directions. Front. Immunol., 12.","DOI":"10.3389\/fimmu.2021.711060"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"6947","DOI":"10.4049\/jimmunol.1001269","article-title":"IL-17 regulates adipogenesis, glucose homeostasis, and obesity","volume":"185","author":"Shen","year":"2010","journal-title":"J. Immunol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1111\/exd.12691","article-title":"Obesity exacerbates imiquimod-induced psoriasis-like epidermal hyperplasia and interleukin-17 and interleukin-22 production in mice","volume":"24","author":"Kanemaru","year":"2015","journal-title":"Exp. Dermatol."},{"key":"ref_28","first-page":"74","article-title":"Clinical Significance of Serum IL-6 and TNF-\u03b1 Levels in Patients with Metabolic Syndrome","volume":"6","author":"Mohammadi","year":"2017","journal-title":"Rep. Biochem. Mol. Biol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"700","DOI":"10.12669\/pjms.37.3.3897","article-title":"Determination of serum tumor necrosis factor-alpha (TNF-\u03b1) levels in metabolic syndrome patients from Saudi population","volume":"37","author":"Ullah","year":"2021","journal-title":"Pak. J. Med. Sci."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1172\/JCI113991","article-title":"Effect of tumor necrosis factor (TNF) on lipid metabolism in the diabetic rat. Evidence that inhibition of adipose tissue lipoprotein lipase activity is not required for TNF-induced hyperlipidemia","volume":"83","author":"Feingold","year":"1989","journal-title":"J. Clin. Investig."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1038\/s42255-021-00470-z","article-title":"Metabolic Messengers: Tumour necrosis factor","volume":"3","author":"Sethi","year":"2021","journal-title":"Nat. Metab."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/j.cell.2015.01.012","article-title":"Hepatic acetyl CoA links adipose tissue inflammation to hepatic insulin resistance and type 2 diabetes","volume":"160","author":"Perry","year":"2015","journal-title":"Cell"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"2751","DOI":"10.1073\/pnas.1920004117","article-title":"Regulation of adipose tissue inflammation by interleukin 6","volume":"117","author":"Han","year":"2020","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1210\/jc.2002-021437","article-title":"Association of low interleukin-10 levels with the metabolic syndrome in obese women","volume":"88","author":"Esposito","year":"2003","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1038\/cr.2015.68","article-title":"Metabolic reprogramming in macrophages and dendritic cells in innate immunity","volume":"25","author":"Kelly","year":"2015","journal-title":"Cell Res."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"313","DOI":"10.23736\/S2784-8671.21.07125-5","article-title":"Use of apremilast\u00ae in the psoriasis treatment: A real-life multicenter Italian experience","volume":"157","author":"Filippi","year":"2022","journal-title":"Ital. J. Dermatol. Venereol."},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Guerra, P., Di Cesare, A., Rosi, E., Scandagli, I., Silvi, G., Nunziati, G., and Prignano, F. (2024). Effects on Lipid Profile after One Year of Apremilast Therapy in Patients with Psoriasis: A Monocentric Experience. Life, 14.","DOI":"10.3390\/life14030395"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1001\/jamadermatol.2022.3862","article-title":"Association of Apremilast with Vascular Inflammation and Cardiometabolic Function in Patients with Psoriasis: The VIP-A Phase 4, Open-label, Nonrandomized Clinical Trial","volume":"158","author":"Gelfand","year":"2022","journal-title":"JAMA Dermatol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1111\/joim.13447","article-title":"The clinical and molecular cardiometabolic fingerprint of an exploratory psoriatic arthritis cohort is associated with the disease activity and differentially modulated by methotrexate and apremilast","volume":"291","author":"Ruiz","year":"2022","journal-title":"J. Intern. Med."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"13872","DOI":"10.1080\/21655979.2022.2085390","article-title":"Protective roles of apremilast via Sirtuin 1 in atherosclerosis","volume":"13","author":"Sui","year":"2022","journal-title":"Bioengineered"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"2290","DOI":"10.18632\/aging.101068","article-title":"The protective role of Sirt1 in vascular tissue: Its relationship to vascular aging and atherosclerosis","volume":"8","author":"Kitada","year":"2016","journal-title":"Aging"},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Schick, M.A., and Schlegel, N. (2022). Clinical Implication of Phosphodiesterase-4-Inhibition. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23031209"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"8537","DOI":"10.1073\/pnas.89.18.8537","article-title":"Mechanism of hormone-stimulated lipolysis in adipocytes: Translocation of hormone-sensitive lipase to the lipid storage droplet","volume":"89","author":"Egan","year":"1992","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1136\/annrheumdis-2015-207963","article-title":"Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis and current skin involvement: A phase III, randomised, controlled trial (PALACE 3)","volume":"75","author":"Edwards","year":"2016","journal-title":"Ann. Rheum. Dis."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"AB89","DOI":"10.1016\/j.jaad.2019.06.346","article-title":"Long-term hemoglobin A1C changes with apremilast in patients with psoriasis and psoriatic arthritis: Pooled analysis of phase 3 esteem and palace trials and phase 3b liberate trial","volume":"81","author":"Puig","year":"2019","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1111\/1346-8138.15293","article-title":"Real life experience of apremilast in psoriasis and arthritis psoriatic patients: Preliminary results on metabolic biomarkers","volume":"47","author":"Mazzilli","year":"2020","journal-title":"J. Dermatol."},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Ikonomidis, I., Pavlidis, G., Kadoglou, N., Makavos, G., Katogiannis, K., Kountouri, A., Thymis, J., Kostelli, G., Kapniari, I., and Theodoropoulos, K. (2022). Apremilast Improves Endothelial Glycocalyx Integrity, Vascular and Left Ventricular Myocardial Function in Psoriasis. Pharmaceuticals, 15.","DOI":"10.3390\/ph15020172"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"19012","DOI":"10.18632\/aging.103665","article-title":"Apremilast ameliorates ox-LDL-induced endothelial dysfunction mediated by KLF6","volume":"12","author":"Wang","year":"2020","journal-title":"Aging"},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Gualtierotti, R., and De Lucia, O. (2019). Efficacy and Metabolic Effect on Serum Lipids of Apremilast in Psoriatic Arthritis: A Case Report. J. Clin. Med., 8.","DOI":"10.3390\/jcm8030398"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.jaad.2015.09.001","article-title":"Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with difficult-to-treat nail and scalp psoriasis: Results of 2 phase III randomized, controlled trials (ESTEEM 1 and ESTEEM 2)","volume":"74","author":"Rich","year":"2016","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1080\/09546634.2020.1801976","article-title":"Apremilast as a target therapy for nail psoriasis: A real-life observational study proving its efficacy in restoring the nail unit","volume":"33","author":"Lanna","year":"2022","journal-title":"J. Dermatol. Treat."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1111\/1346-8138.16074","article-title":"Apremilast improves quality of life and ultrasonography parameters in patients with nail psoriasis: A prospective cohort study","volume":"48","author":"Vidal","year":"2021","journal-title":"J. Dermatol."},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"Galluzzo, M., Talamonti, M., Cioni, A., Maffei, V., Shumak, R.G., Tofani, L., Bianchi, L., and Campione, E. (2022). Efficacy of Tildrakizumab for the Treatment of Difficult-to-Treat Areas: Scalp, Nail, Palmoplantar and Genital Psoriasis. J. Clin. Med., 11.","DOI":"10.3390\/jcm11092631"}],"container-title":["Pharmaceuticals"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1424-8247\/17\/8\/989\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T15:24:03Z","timestamp":1760109843000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1424-8247\/17\/8\/989"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,26]]},"references-count":53,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2024,8]]}},"alternative-id":["ph17080989"],"URL":"https:\/\/doi.org\/10.3390\/ph17080989","relation":{},"ISSN":["1424-8247"],"issn-type":[{"value":"1424-8247","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,26]]}}}